[O8] Oral Session 8　Lung Cancer / Thoracic Cancer 2（Immune Checkpoint Inhibitors）
【E】

[O8-4] KEYNOTE-042: 5-Year Update of 1L Pembrolizumab in Asian Patients With Locally Advanced/Metastatic PD-L1-Positive NSCLC

^○Kaoru Kubota¹, Byoung Chul Cho², Vichien Srimuninnimit³, Yu Fan⁴, Jianying Zhou⁵, Li Zhang⁶, Qing Zhou^7,8, Yukio Hosomi⁹, Hiroaki Takeoka¹⁰, Rinee Mukherjee¹¹, Wei Fu¹¹, Fabricio Souza¹¹, Tony S. K. Mok¹², Li Zhang¹³ (1.Department of Pulmonary Medicine and Oncology, Nippon Medical School Hospital, Tokyo, Japan, 2.Division of Medical Oncology, Yonsei Cancer Center, Seoul, South Korea, 3.Department of Medicine, Siriraj Hospital, Bangkok, Thailand, 4.Thoracic Medical Oncology Department of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China, 5.Department of Respiratory Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou, China, 6.Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, 7.Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Lung Cancer Institute, Guangzhou, China, 8.Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China, 9.Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, 10.Department of Respiratory Medicine, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan, 11.Merck & Co., Inc., Kenilworth, NJ, USA, 12.Clinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Shatin, Hong Kong, China, 13.Peking Union Medical College Hospital, Beijing, China)